The short answer
Ipamorelin and CJC-1295 are two synthetic peptides classified as growth hormone (GH) secretagogues: rather than delivering GH from the outside, they stimulate the pituitary gland to release its own GH. They act on two different receptors. Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHS-R), the same receptor targeted by ghrelin. CJC-1295 is an analog of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor. Both pathways converge on the same GH-producing cell, the somatotroph.
This article is an educational document. The bio-peptides.fr website supplies compounds intended exclusively for in vitro and preclinical research (Research Use Only). No human dosing, no usage protocol and no therapeutic or performance claim appears here. The aim is to present the published science rigorously, clearly separating what is demonstrated from what remains hypothetical.
The central message: the scientific literature describes plausible mechanisms and measurable pharmacological effects on GH secretion, but clinical studies are few, involve small samples and cover short durations. Long-term safety data are almost nonexistent. Both molecules also appear on the World Anti-Doping Agency (WADA) prohibited list, in and out of competition.
The somatotropic axis: how the body regulates GH
Growth hormone secretion is driven by the hypothalamic-pituitary axis, often called the somatotropic axis. The hypothalamus produces two opposing signals. GHRH (growth hormone-releasing hormone) stimulates the synthesis and release of GH by somatotroph cells of the anterior pituitary. Somatostatin (SRIF) does the opposite: it restrains GH release. The dynamic balance between these two hormones determines, minute by minute, how much GH is released into the circulation.
A third player joins this duo: ghrelin, a peptide produced mainly by the stomach and identified as the endogenous ligand of the growth hormone secretagogue receptor (GHS-R). Ghrelin amplifies GH release and acts as a signal of nutritional status, linking energy metabolism to growth. Work by Tannenbaum, Epelbaum and Bowers (2003) showed that ghrelin's action on GH depends on an intact GHRH system and that somatostatin antagonizes this action at the pituitary level: the three signals are therefore tightly interwoven.
A key feature of this axis is pulsatility. GH is not secreted continuously but in bursts, or pulses, separated by low periods. This pulsatile profile results from the alternation between peaks of GHRH and peaks of somatostatin. Pulsatility is biologically meaningful: many of GH's effects depend on the temporal pattern of its secretion, not only on its average concentration. Understanding this point is essential to interpret what secretagogues do, and do not do.
Secretagogue versus exogenous GH: two opposite logics
A secretagogue is a substance that triggers the secretion of another substance by a cell. In the context of the somatotropic axis, a GH secretagogue contains no GH: it stimulates the pituitary to release the GH the gland has itself synthesized. This is a major conceptual difference from exogenous recombinant GH (somatropin), which is the hormone itself, administered directly.
This distinction has pharmacological consequences. With a secretagogue, the released GH remains subject, at least in part, to physiological feedback loops: somatostatin and IGF-1 can modulate the response, which tends to preserve some degree of pulsatility. With exogenous GH, the concentration is imposed externally and bypasses these loops, producing more sustained and less physiological levels. This nuance is frequently cited in the literature as a reason to study secretagogues, without constituting proof of clinical superiority.
There are two broad families of peptide secretagogues. GHRH analogs, such as CJC-1295, mimic the natural stimulatory signal and bind the GHRH receptor. Ghrelin-family peptides, known as GHRPs or ghrelin mimetics, such as ipamorelin, act on the GHS-R. Both families raise GH, but through different receptors and intracellular mechanisms, which explains the research interest in combining them.
Ipamorelin: a selective GHS-R agonist
Ipamorelin is a synthetic pentapeptide first described by Raun and colleagues in the European Journal of Endocrinology in 1998. The authors present it as the first GH secretagogue with a selectivity for GH release comparable to that of GHRH. It binds the GHS-R, the ghrelin receptor, and stimulates GH release with in vitro and in vivo potency of the same order as GHRP-6, a historical reference in this class.
The striking finding of Raun's study concerns selectivity. Other GHRP-family peptides, such as GHRP-6 and GHRP-2, also increase plasma concentrations of ACTH and cortisol, two stress hormones. In the models used, ipamorelin did not cause a significant rise in ACTH or cortisol, even at doses well above the GH-releasing threshold. The authors also report the absence of a notable effect on prolactin. This selectivity is why ipamorelin is often described as a more targeted secretagogue than its predecessors.
It is important to stay precise about the scope of these results. The seminal 1998 study is a pharmacological characterization relying largely on animal and cellular models. It establishes a profile of selectivity and potency, not a demonstration of long-term clinical efficacy or safety in humans. The conclusions should therefore be read as a description of mechanism, robust within its experimental frame, but permitting no extrapolation toward human use.
CJC-1295: a long-acting GHRH analog
CJC-1295 is a synthetic analog of GHRH, more precisely a modified version of the active fragment GRF(1-29). Native GHRH has a very short half-life, on the order of a few minutes, because it is rapidly degraded by plasma enzymes. CJC-1295 introduces amino acid modifications that slow this degradation and prolong the peptide's action.
One technical distinction is central: the presence or absence of a DAC, for Drug Affinity Complex. The version with DAC carries a group that binds covalently to blood albumin, which considerably extends the half-life. The study by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2006, evaluated this form in healthy adults and estimated its half-life at between 5.8 and 8.1 days. After a single injection, the authors observed a GH elevation persisting for several days and an IGF-1 rise sustained for about nine to eleven days, with a cumulative effect upon repeated administration. No serious adverse reactions were reported in these short trials.
The version without DAC, often called Mod GRF(1-29) or CJC-1295 no-DAC, lacks this albumin-binding system. Its half-life is far shorter, on the order of a few dozen minutes, producing a shorter GH stimulation closer to a pulse. This kinetic difference explains why the two forms are not interchangeable in research protocols and why confusion between the two names is a frequent source of error in the grey literature.
Why research studies these peptides in combination
The interest in combining a GHRH analog with a ghrelin mimetic comes from their mechanistic complementarity. Both receptors, the GHRH receptor and the GHS-R, are expressed on the somatotroph cell but activate partly distinct intracellular pathways. GHRH acts mainly via cyclic AMP production, whereas the ghrelin pathway mobilizes intracellular calcium in particular. Engaging both pathways simultaneously produces, in several experimental models, a GH response greater than the sum of the two stimulations taken separately.
This potentiation has been documented at the cellular level. A study published in Endocrinology in 2002 showed that ghrelin and GH secretagogues amplify GHRH-induced cyclic AMP production in cells expressing both receptors. Physiologically, the work of Tannenbaum and colleagues recalls that ghrelin's action requires a functional GHRH system. These observations provide a rational basis for studying combinations pairing a GHRH analog such as CJC-1295 with a GHS-R agonist such as ipamorelin.
It is nonetheless essential to distinguish mechanistic plausibility from clinical proof. The described synergy rests mostly on cellular and animal models, or on acute measurements of GH secretion in humans. The fact that a combination amplifies a hormonal signal in the short term says nothing about its functional effects, its safety or its real value over prolonged periods. The literature justifies exploration in research; it justifies no applied conclusion.
The limits of the available data
Caution is warranted because the body of evidence is thin. For ipamorelin, the reference remains largely the 1998 preclinical characterization, supplemented by a few exploratory studies. For CJC-1295 with DAC, Teichman's 2006 trial is authoritative, but it involves a small number of participants and follow-up durations of a few weeks. This work establishes a pharmacological profile, not an efficacy and safety dossier comparable to that of an approved medicine.
Several limitations recur systematically. Sample sizes are small, which reduces statistical power and the ability to detect rare adverse effects. Observation durations are short, often on the order of days to weeks, whereas modulating an endocrine axis could have consequences over months or years. Long-term safety data are almost absent, leaving important questions open, notably about the effects of sustained stimulation of the GH and IGF-1 axis.
A further point concerns the quality and origin of products circulating outside pharmaceutical channels. Preparations sold as research compounds can vary in purity, identity and concentration. This heterogeneity further complicates data interpretation and underscores the importance of rigorous analytical characterization in any research work. In short, the state of knowledge permits describing mechanisms, not formulating recommendations.
Regulatory status and anti-doping ban
From a regulatory standpoint, neither ipamorelin nor CJC-1295 holds a marketing authorization as a medicine in France or the European Union for general use. They are handled within a strictly experimental framework. On the bio-peptides.fr website, these compounds are offered exclusively for in vitro and preclinical research (Research Use Only), excluding any human or veterinary, diagnostic or therapeutic use.
Both molecules appear on the World Anti-Doping Agency (WADA) list of prohibited substances and methods, in the S2 category of peptide hormones, growth factors and related substances. The growth hormone releasing factors subcategory explicitly covers GHRH analogs, where CJC-1295 is named, as well as GH secretagogues and their mimetics, where ipamorelin is named. These substances are prohibited at all times, in and out of competition, and are classified as non-specified substances.
For any athlete subject to anti-doping testing, the use of these peptides therefore constitutes a rule violation, regardless of any medical consideration. This information is provided factually and educationally. It constitutes neither advice nor encouragement, and it does not alter the Research Use Only framework reiterated throughout this article: the compounds described here are intended for research and nothing else.
Key takeaways
The somatotropic axis is regulated by a three-way interplay between stimulatory GHRH, inhibitory somatostatin and amplifying ghrelin, with an inherently pulsatile GH secretion. Secretagogues do not deliver GH: they prompt the pituitary to release its own, which conceptually distinguishes them from exogenous GH.
Ipamorelin is a selective GHS-R agonist, notable in Raun's 1998 study for its reported absence of effect on cortisol and prolactin. CJC-1295 is a GHRH analog whose DAC version strongly prolongs the half-life, as Teichman showed in 2006. Studying them in combination rests on a documented mechanistic synergy between the GHRH and ghrelin pathways.
Finally, all of these data remain limited by small samples, short durations and the absence of long-term follow-up, and both compounds are banned by WADA. They fall strictly within the scope of research and are, on this blog, the subject of no usage recommendation.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between ghrelin and somatostatin/GHRH in regulation of pulsatile GH secretion. Endocrinology. 2003;144(3):967-974.
- Cunha SR, Mayo KE. Ghrelin and GH secretagogues potentiate GHRH-induced cyclic AMP production. Endocrinology. 2002;143(12):4570-4582.
- Ghigo E, et al. Development of growth hormone secretagogues (review). 2005.
- World Anti-Doping Agency (WADA). Prohibited List, category S2.